APR Is Flying, LG H&H Is Pivoting, Cellreturn Has Collapsed — The Three Faces of the Beauty Device Market
Overview
Korea's home beauty device market grew more than 3x in five years, from KRW 500B in 2018 to KRW 1.6T in 2023. But within that one growing market, companies' fortunes have split in opposite directions. APR is posting record results on twin engines of cosmetics and devices; LG Household & Health Care, its core cosmetics business faltering, is belatedly pivoting into devices; and Cellreturn, once the market's #1 LED mask maker, saw revenue evaporate 90% after a false-advertising crackdown and still hasn't recovered five years later.
Korea's home beauty device market grew from KRW 500B in 2018 to KRW 1.6T in 2023 — more than tripling in five years. Globally, the market is projected to grow from $1.32B in 2024 to $4.81B in 2034, a 13.8% CAGR. Behind this growth is the "at-home-ification" of aesthetic treatments — procedures once available only at dermatology clinics and aesthetic studios are being miniaturized into home devices. But within this single growing market, companies' fortunes are splitting in opposite directions. APR keeps setting record quarterly results on the twin engines of cosmetics and devices; LG Household & Health Care, once Korea's #1 cosmetics company, is belatedly shifting its center of gravity toward devices as its core business falters; and Cellreturn, once the #1 LED mask maker, saw revenue evaporate 90% after a single regulatory crackdown and still hasn't recovered five years on.
Mapping the Market — Home Beauty Devices Split by Technology
Home beauty devices fall into several categories that differ completely in character depending on the underlying technology.
| Technology | Mechanism | Claimed Benefits | Representative Brands | Price Tier |
|---|---|---|---|---|
| RF (radio frequency) | Delivers heat to the dermis to stimulate collagen production | Firmness, lifting, wrinkle reduction | Medicube AGE-R, Dualsonic, TriPollar | Premium |
| LED phototherapy | Stimulates cell activity with wavelength-specific light | Collagen production (red), reduced acne bacteria (blue), calming (yellow) | LG Pra:L, Cellreturn, CurrentBody | Mid |
| EMS / microcurrent | Induces muscle contraction via micro-current | Immediate contouring, reduced puffiness | NuFACE, Medicube EMS | Mid |
| Ultrasound | Delivers energy via ultrasonic vibration | Improves product absorption, skin texture | — | Mid-low |
| Electroporation | Electrical stimulation opens micro-channels for ingredient penetration | Ampoule absorption, hydration, brightening | — | Mid |
| IPL / laser hair removal | Suppresses hair follicle growth with light energy | At-home hair removal | Philips Lumea, Braun Silk Expert | Mid-high |
| Scalp / hair-loss devices | Improves scalp environment via LED, laser, vibration, microcurrent | Improved scalp blood flow, hair-loss support | — | Mid |
Of these, RF lifting devices — a home adaptation of the dermatology clinic procedure Thermage — command the highest price tier and best repeat-purchase rates, making them the market's premium category. LED masks are the most mass-market category, being nearly painless and simple to use. Scalp and hair-loss devices are the fastest-growing emerging category, driven by an aging population and rising rates of hair loss. Layer on top of all this the recent addition of AI-based skin diagnostics, app connectivity, and usage-data analytics, and the category is evolving into "smart beauty devices."
Core Insight #1 — APR Is Flying on Twin Engines: Cosmetics and Devices
The clearest winner in this market is APR. Medicube cosmetics and AGE-R beauty devices each generated more than KRW 130B in H1 2026, serving as the company's two growth pillars (APR's company-wide Q2 revenue was KRW 767.5B with a 24.8% operating margin — RIT covered the regional growth story behind that in a separate earlier piece). AGE-R's RF-class devices, like the Booster Healer and Booster Pro, sit in the highest-price, highest-margin category of the home beauty market, and APR has established itself as one of the few companies with both cosmetics brand power and device technology at once in that category. Being able to cross-sell cosmetics and devices under one brand functions as a structural advantage over single-category specialists.
Core Insight #2 — LG H&H Pivots to Devices as Cosmetics Falters
On the other side sits LG Household & Health Care, the traditional powerhouse of Korea's cosmetics industry. LG H&H's FY2025 revenue came to KRW 6.3555T (-6.7%) and operating profit to KRW 170.7B (-62.8%), a sharp deterioration in the profitability of its core cosmetics business. Against that backdrop, the company took direct ownership of its device business last June, taking over the "Pra:L" trademark and associated social-media channels from LG Electronics. It has since accelerated its beauty device push, launching the roughly KRW 100,000 "Pra:L Superform Galvanic Booster." Industry commentary has gone as far as saying "Pra:L instead of Whoo" — meaning a company long defined by its Whoo cosmetics brand is now looking for a new growth path in devices, a category it entered as a latecomer, as its core business wobbles. The company did in fact post a Q2 2026 rebound — revenue of KRW 1.6574T (+3.3%) and operating profit of KRW 102.8B (+87.5%) — though how much of that rebound is attributable to device expansion isn't separately disclosed. Still, the fact that the company itself is emphasizing Pra:L as a core growth pillar is telling on its own. What makes this particularly interesting is the timing: this shift coincides with the moment, in August 2025, when APR overtook LG H&H by market cap to become Korea's largest beauty company. The company that lost the top spot in Korean cosmetics appears to be belatedly following the growth formula (cosmetics + device hybrid) of the very company that took that spot from it.
Core Insight #3 — Cellreturn Shows How Regulatory Risk Can Topple a Market Leader
The third face is closer to a warning. Cellreturn (operated by STG24), the company that pioneered the LED mask market, was the #1 player with KRW 128.5B in revenue in 2019. That same September, Korea's Ministry of Food and Drug Safety flagged 48 LED mask products for false advertising — the problem being that they were marketed with claims like "wrinkle improvement," "facial lifting," and "reduces blemishes and acne" without medical device approval. Reports of side effects followed — itching, redness, acne, and even retinal damage and risk of blindness — serious enough that a victims' community sprang up on Naver. Revenue crashed nearly 90% to KRW 14.9B in 2020, and even five years later, in 2024, revenue was still just KRW 4.1B (-67.7% year over year) with an operating loss of KRW 4.75B (widening 82.7%) — deterioration, not recovery. Retained earnings have sunk to -KRW 10.7B, ruling out any dividend, and with cash and equivalents of just KRW 130 million against current liabilities of KRW 54.1B (including KRW 52.2B in short-term borrowings), the company faces a liquidity crisis with a debt ratio of roughly 180%. That it has set aside 82.9% (KRW 12.1B) of its KRW 14.6B in accounts receivable as bad-debt allowance shows the company itself doesn't expect to collect most of it. It's the most extreme example available of what happens when a category pioneer fails to manage regulatory compliance.
Business Impact — What These Three Faces Reveal About the Market's Structure
Line these three cases up, and the structure of the home beauty device market comes into focus. First, a company with both brand power and technology (APR) can combine a high-margin category (RF) with cosmetics to lead the market. Second, for a legacy company whose core business is struggling (LG H&H), devices can offer a new growth path — but entering as a latecomer means the challenge of closing the gap with already-established brands. Third, this market carries unusually high regulatory risk — many home beauty devices sit at the boundary between cosmetics and medical devices, where a single efficacy claim or ad slogan can shake an entire company. Cellreturn's case isn't an outlier; the industry as a whole should recognize it as a risk structurally embedded in this market.
Practical Implications
- Beauty device MDs/buyers: Build placement strategy around the fact that categories differ fundamentally in character — RF carries high price and margin but also a high barrier to entry, while LED has strong mass appeal but, as Cellreturn shows, is the category most exposed to regulatory risk
- Brand marketing/regulatory affairs teams: Cellreturn proved that using terms like "lifting" or "wrinkle improvement" without medical device approval can destabilize an entire company. New product ad copy should always be pre-reviewed against Ministry of Food and Drug Safety standards
- Legacy beauty company strategy teams: A diversification strategy into devices, as LG H&H is doing when its core cosmetics profitability wobbles, can work — but success hinges on how quickly the gap with an already brand-established latecomer-turned-leader (APR) can be closed
- Investment/analyst teams: When evaluating home beauty device companies, check regulatory-risk exposure separately from growth rate. As Cellreturn shows, a single regulatory issue can wreck a balance sheet for more than five years, which warrants pricing in a corresponding risk premium
Conclusion
The home beauty device market has more than tripled in five years, but within it, winners and losers have been separated not by technology but by execution and risk management. APR leads the market by combining cosmetics and devices; LG H&H is belatedly throwing its weight behind this market to offset a wobbling core business; and Cellreturn, having failed to manage regulatory risk, still hasn't recovered five years after losing its position as market leader. Approach this industry by looking only at the headline market-growth number, and you miss the real variables that actually decide a company's fate here — brand integration and regulatory-risk management.
Looking at these three companies side by side, what struck me most is that home beauty devices are less a "technology market" than a "trust market." Whether it's RF, LED, or EMS, in the end it's a product where a consumer puts a device that emits electricity, heat, or light directly onto their face. The moment a company overstates its efficacy claims, consumer trust collapses — and as Cellreturn shows, a single regulatory issue can leave an entire company unable to recover for more than five years. I'd argue APR is ahead in this market not purely because of its technology, but because it extended the trust it built as a cosmetics brand into devices.
LG H&H's pivot to Pra:L carries a broader lesson for Korean retail and consumer goods generally. A once-dominant company belatedly following a latecomer's business model is a reminder that even a category you're winning today can be overtaken in a hurry if you get complacent. That said, given LG H&H still holds a firmly established cosmetics asset in Whoo, whether its device business can generate real synergy with cosmetics is, I think, the key question in whether it can catch up to APR.
Finally, Cellreturn's case should be read as a warning to Korea's broader beauty startup scene. Among today's fast-growing new device brands, there are almost certainly some prioritizing marketing speed over regulatory approval. The fact that a former market leader still hasn't escaped financial crisis five years later is about as clear a piece of evidence as you'll find that, in this industry, regulatory compliance is a far more fundamental competitive advantage than growth speed.